I have been going through the history of UCM financials and thought some of you would like to see. The current financial year does offer the potential for a dramatic increase in revenues if the current quarter produces similar results to the last quarter. Any input would be greatly appreciated, and hopefully can lead to some new discussions.
The question that will be answered for me in the following quarter is whether the increased sales revenue for Q3 was simply a delayed result from regulatory issues in China, in which case the year may finish with revenues below 4,000,000 and within the normal range since 2016. Or whether we are seeing real growth in sales. If we come close to 2 million in revenues for the quarter, matching Q3 revenues, that will see sales around 5 million for the year which would represent annual revenues growth of 40%. Obviously if we exceed that, all the better.
Any input on how 40% revenue growth compares to the medical device industry, and other similar companies would be helpful too.
UCM Price at posting:
23.0¢ Sentiment: None Disclosure: Held
